The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved MSD’s anti-programmed death receptor-1 (PD-1) therapy KEYTRUDA (pembrolizumab) for lung and urothelial cancer indications. The approved indications are non-small cell lung carcinoma (NSCLC) and radically unresectable urothelial carcinoma. The gold standard of business intelligence.
The first allows for the use of KEYTRUDA with chemotherapy as a neoadjuvant treatment, followed by its continuation as monotherapy for adjuvant treatment in NSCLC patients. This approval stems from the results of the Phase III KEYNOTE-671 clinical trial. KEYTRUDA is also approved for use along with Padcev (enfortumab vedotin-ejfv) as a first-line treatment for patients with radically unresectable urothelial carcinoma.
The decision is based on results from the Phase III KEYNOTE-A39 (EV-302) clinical trial, carried out in partnership with and Astellas. Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research.
Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form KEYTRUDA monotherapy has also been approved for patients with radically unresectable urothelial carcinoma ineligible for any platinum-containing chemotherapy.
This indication is supported by fin.
